Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.50 |
| ▸ | EPOR | P19235 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16350545 | 0.92 | GLP1R (0.46) | GLP1REPORTSHRFOLH1 | |
| SCHEMBL13805654 | 0.89 | GLP1R (0.53) | GLP1RTSHR | |
| SCHEMBL13805653 | 0.88 | GLP1R (0.57) | GLP1REPHX2 | |
| SCHEMBL20900405 | 0.88 | GLP1R (0.57) | GLP1REPOREPHX2ADRA1AFOLH1 | |
| SCHEMBL13805652 | 0.88 | GLP1R (0.49) | GLP1RTSHR | |
| SCHEMBL12118710 | 0.88 | GLP1R (0.68) | GLP1RFOLH1 | |
| SCHEMBL16638310 | 0.88 | GLP1R (0.68) | GLP1RFOLH1 | |
| SCHEMBL16638275 | 0.88 | GLP1R (0.68) | GLP1RFOLH1 | |
| SCHEMBL12118656 | 0.88 | GLP1R (0.68) | GLP1RFOLH1 | |
| SCHEMBL16711028 | 0.88 | GLP1R (0.68) | GLP1RFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713344-B2 | Acylated oxyntomodulin peptide analog | DONG-A ST CO., LTD. (KR) | 2023-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713344-B2 | Acylated oxyntomodulin peptide analog | GLP1R, GIPR, GPR119 | GLP1R 1/4885EPOR 854/4885TSHR 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.